On August 22, "United Imaging Healthcare," an investee company of Yuanhe Chencun-managed fund-of-funds and backed by Source Capital, officially listed on the STAR Market of the Shanghai Stock Exchange, with stock code: 688271.

United Imaging Healthcare was founded in 2011 and is dedicated to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments, as well as digital and intelligent healthcare solutions. Since its establishment, the company has consistently invested heavily in research and development, focusing on mastering core technologies in key areas of large-scale medical devices such as medical imaging systems and radiotherapy products. In terms of technological achievements, most core components across its product lines are now developed and manufactured in-house, significantly reducing reliance on imports and keeping associated risks under control.

As of the end of 2021, United Imaging Healthcare had been granted more than 1,700 authorized invention patents, including over 1,200 domestic invention patents and more than 400 overseas invention patents. Additionally, the company has taken the lead in nearly 40 national and provincial-level R&D projects and now equips nearly 900 top-tier Grade III hospitals across China.

Since its establishment, United Imaging Healthcare has consistently focused on driving breakthroughs in high-end medical equipment through relentless R&D investment. Relying on a talent strategy that has been steadily advanced over the years, coupled with the positive feedback generated by its equity incentive programs, the company has built a comprehensive talent pool spanning core technology development, product design, preclinical research, clinical trials, and regulatory approvals. Today, United Imaging Healthcare boasts more than 2,000 R&D professionals—accounting for over 35% of the company’s total workforce—and possesses robust, integrated R&D capabilities along with a fully developed intellectual property framework. The company has mastered cutting-edge, critical technologies at the forefront of the high-end medical imaging industry, effectively breaking the technological monopoly held by foreign competitors. Meanwhile, its integrated diagnostic-and-therapeutic product portfolio rivals that of global industry leaders.

This IPO on the STAR Market has enabled United Imaging Healthcare to raise 10.988 billion yuan, which will be allocated to next-generation product development projects, an industrialization fund for high-end medical imaging equipment, replenishment of working capital, expansion of its marketing and service network, and initiatives to enhance IT infrastructure. These investments will further support the company’s scalable and global growth, positioning United Imaging Healthcare as a world-class leader in medical innovation.